文献速递慢阻肺呼吸道感染

CRP指导慢阻肺急性加重住院患者抗生素治疗

CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions.
PubMed 文献 · Eur Respir J · 2019-05-23

一项随机对照试验比较CRP指导与GOLD症状策略指导抗生素治疗慢阻肺急性加重住院患者。CRP组抗生素使用率显著低于GOLD组(31.7% vs 46.2%,p=0.028),30天治疗失败率、至下次加重时间、住院时长及不良事件均无显著差异。

要点

  • CRP≥50 mg·L-1指导抗生素可减少慢阻肺急性加重住院患者抗生素使用。
  • CRP指导组与GOLD症状指导组的30天治疗失败率相近。
  • 两组住院时长、症状评分、生活质量及严重不良事件无差异。

核心结论

  • 以CRP≥50 mg·L-1指导慢阻肺急性加重住院患者抗生素治疗,可显著减少抗生素使用,且未增加不良事件。

研究设计与样本

  • 随机对照试验,纳入住院的慢阻肺急性加重患者,CRP组101例,GOLD组119例。

主要发现

  • CRP组抗生素治疗比例31.7%,GOLD组46.2%,差异有统计学意义(p=0.028;校正OR 0.178,95%CI 0.077-0.411,p=0.029)。
  • 30天治疗失败率CRP组44.5%,GOLD组45.5%,差异无统计学意义(p=0.881;校正OR 1.146,95%CI 0.649-1.187,p=0.630)。
  • 至下次加重时间CRP组32天,GOLD组28天,差异无统计学意义(p=0.713;校正HR 0.878,95%CI 0.649-1.187,p=0.398)。
  • 住院时长CRP组7天,GOLD组6天,差异无统计学意义(p=0.206)。
  • 第30天症状评分、生活质量及严重不良事件两组均无差异。

关键数值与推荐

  • CRP策略以CRP≥50 mg·L-1作为启动抗生素治疗的阈值。
  • GOLD策略依据患者报告的症状。

临床怎么用

  • 对慢阻肺急性加重住院患者,可考虑以CRP≥50 mg·L-1作为启动抗生素治疗的参考阈值以减少抗生素暴露。

局限性

  • 原文指出需要进一步研究以评估结果的普遍适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of antibiotics in acute exacerbations of chronic obstructive pulmonary disease (COPD) is controversial and a biomarker identifying patients who benefit from antibiotics is mandatory. We performed a randomised, controlled trial in patients with acute exacerbations of COPD, comparing C-reactive protein (CRP)-guided antibiotic treatment to patient reported symptoms in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy, in order to show a reduction in antibiotic prescription.Patients hospitalised with acute exacerbations of COPD were randomised to receive antibiotics based either on the GOLD strategy or according to the CRP strategy (CRP ≥50 mg·L-1).In total, 101 patients were randomised to the CRP group and 119 to the GOLD group. Fewer patients in the CRP group were treated with antibiotics compared to the GOLD group (31.7% versus 46.2%, p=0.028; adjusted odds ratio (OR) 0.178, 95% CI 0.077-0.411, p=0.029). The 30-day treatment failure rate was nearly equal (44.5% in the CRP group versus 45.5% in the GOLD-group, p=0.881; adjusted OR 1.146, 95% CI 0.649-1.187, p=0.630), as was the time to next exacerbation (32 days in the CRP group versus 28 days in the GOLD group, p=0.713; adjusted hazard ratio 0.878, 95% CI 0.649-1.187, p=0.398). Length of stay was similar in both groups (7 days in the CRP group versus 6 days in the GOLD group, p=0.206). On day-30, no difference in symptom score, quality of life or serious adverse events was detected.Use of CRP as a biomarker to guide antibiotic treatment in severe acute exacerbations of COPD leads to a significant reduction in antibiotic treatment. In the present study, no differences in adverse events between both groups were found. Further research is needed for the generalisability of these findings.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Prins HJ, Duijkers R, van der Valk P, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. Eur Respir J. 2019. PMID: 30880285. doi:10.1183/13993003.02014-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。